AIP
ELVN icon

Ameritas Investment Partners’s Enliven Therapeutics ELVN Stock Holding History

Ameritas Investment Partners’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$135K Hold
3,449
– – ﹤0.01% 1508
2025
Q4 		$53.1K Hold
3,449
– – ﹤0.01% 2078
2025
Q3 		$70.6K Hold
3,449
– – ﹤0.01% 1902
2025
Q2 		$69.2K Hold
3,449
– – ﹤0.01% 1980
2025
Q1 		$67.9K Hold
3,449
– – ﹤0.01% 1934
2024
Q4 		$77.6K Hold
3,449
– – ﹤0.01% 1932
2024
Q3 		$88.1K Hold
3,449
– – ﹤0.01% 1872
2024
Q2 		$80.6K Buy
3,449
+1,521
+79% +$32K ﹤0.01% 1857
2024
Q1 		$33.9K Hold
1,928
– – ﹤0.01% 2337
2023
Q4 		$26.7K Hold
1,928
– – ﹤0.01% 2455
2023
Q3 		$26.3K Hold
1,928
– – ﹤0.01% 2418
2023
Q2 		$39.4K Buy
+1,928
New +$39K ﹤0.01% 2190
2021
Q2 		– Sell
-109
Closed -$4K – 3104
2021
Q1 		$4K Hold
109
– – ﹤0.01% 3026
2020
Q4 		$10K Hold
109
– – ﹤0.01% 2774
2020
Q3 		$9K Hold
109
– – ﹤0.01% 2758
2020
Q2 		$12K Buy
+109
New +$12.2K ﹤0.01% 2622

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameritas Investment Partners's ELVN Position: Q1 2026 in Review

Ameritas Investment Partners held its Enliven Therapeutics (ELVN) position steady in Q1 2026 at 3,449 shares worth $135K. The position accounts for ﹤0.01% of the portfolio, ranked #1508.

Ameritas Investment Partners first reported a position in ELVN in Q2 2020 and has held it in 16 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Ameritas Investment Partners held 3,449 shares of Enliven Therapeutics worth $135K as of Q1 2026.
  • Ameritas Investment Partners left its Enliven Therapeutics share count unchanged in Q1 2026.
  • Enliven Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1508 holding.
  • Ameritas Investment Partners first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 16 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.